Safety and efficacy evaluation of carnosine, an endogenous neuroprotective agent for ischemic stroke.

Bae ON, Serfozo K, Baek SH, Lee KY, Dorrance A, Rumbeiha W, Fitzgerald SD, Farooq MU, Naravelta B, Bhatt A, Majid A

Stroke18 Dec 2012Cited by 65 (Europe PMC)

PMID23250994PMCIDPMC3678096DOI10.1161/strokeaha.112.673954PepBankPUB-23250994

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with transient cerebral artery occlusion, intravenous carnosine showed dose-dependent cerebroprotection with a therapeutic window of 6 hours.
In plain wordsIn rats with transient stroke, carnosine protected the brain with a treatment window of 6 hours.
Peptide
L-carnosine
Outcome
IncreaseTransient stroke cerebroprotection
Study
ratsn: not reported in source
permanent or transient middle cerebral artery occlusion
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · intravenousAs given in this study (rats).
Source sentences
Summary
Intravenous treatment with carnosine exhibited robust cerebroprotection in a dose-dependent manner, with long clinically relevant therapeutic time windows of 6 hours and 9 hours in transient and permanent models, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Efficacy and safety of carnosine treatment was evaluated in rat models of permanent or transient middle cerebral artery occlusion.
Report a problemFND-2325099401
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with permanent cerebral artery occlusion, intravenous carnosine showed dose-dependent cerebroprotection with a therapeutic window of 9 hours.
In plain wordsIn rats with permanent stroke, carnosine protected the brain with a treatment window of 9 hours.
Peptide
L-carnosine
Outcome
IncreasePermanent stroke cerebroprotection
Study
ratsn: not reported in source
permanent or transient middle cerebral artery occlusion
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · intravenousAs given in this study (rats).
Source sentences
Summary
Intravenous treatment with carnosine exhibited robust cerebroprotection in a dose-dependent manner, with long clinically relevant therapeutic time windows of 6 hours and 9 hours in transient and permanent models, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Efficacy and safety of carnosine treatment was evaluated in rat models of permanent or transient middle cerebral artery occlusion.
Report a problemFND-2325099402
03AnimalAnimal study (in vivo)Efficacy outcome
In rat stroke models, carnosine-associated histological improvements persisted on the 14th day after stroke onset.
In plain wordsIn rats with stroke, tissue improvements with carnosine persisted to the 14th day.
Peptide
L-carnosine
Outcome
IncreaseSustained histological improvement
Study
ratsn: not reported in source
permanent or transient middle cerebral artery occlusion
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · intravenousAs given in this study (rats).
Source sentences
Summary
Histological outcomes and functional improvements including motor and sensory deficits were sustained on 14th day poststroke onset.
1 context sentence(design, population, supporting numbers)
Summary · context
Efficacy and safety of carnosine treatment was evaluated in rat models of permanent or transient middle cerebral artery occlusion.
Report a problemFND-2325099403
04AnimalAnimal study (in vivo)Efficacy outcome
In rat stroke models, motor improvements with carnosine persisted on the 14th day after stroke onset.
In plain wordsIn rats with stroke, movement improvements with carnosine persisted to the 14th day.
Peptide
L-carnosine
Outcome
IncreaseSustained motor improvement
Study
ratsn: not reported in source
permanent or transient middle cerebral artery occlusion
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
Dose not stated · intravenousAs given in this study (rats).
Source sentences
Summary
Histological outcomes and functional improvements including motor and sensory deficits were sustained on 14th day poststroke onset.
1 context sentence(design, population, supporting numbers)
Summary · context
Efficacy and safety of carnosine treatment was evaluated in rat models of permanent or transient middle cerebral artery occlusion.
Report a problemFND-2325099404
05AnimalAnimal study (in vivo)Efficacy outcome
In rat stroke models, sensory improvements with carnosine persisted on the 14th day after stroke onset.
In plain wordsIn rats with stroke, sensory improvements with carnosine persisted to the 14th day.
Peptide
L-carnosine
Outcome
IncreaseSustained sensory improvement
Study
ratsn: not reported in source
permanent or transient middle cerebral artery occlusion
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated · intravenousAs given in this study (rats).
Source sentences
Summary
Histological outcomes and functional improvements including motor and sensory deficits were sustained on 14th day poststroke onset.
1 context sentence(design, population, supporting numbers)
Summary · context
Efficacy and safety of carnosine treatment was evaluated in rat models of permanent or transient middle cerebral artery occlusion.
Report a problemFND-2325099405
06AnimalAnimal study (in vivo)Safety outcome
In rat stroke models, safety assessments found no evidence of carnosine adverse effects or toxicity.
In plain wordsIn rats with stroke, carnosine safety assessments found no evidence of adverse effects or toxicity.
Peptide
L-carnosine
Outcome
No significant changeAdverse effects and toxicity
Study
ratsn: not reported in source
permanent or transient middle cerebral artery occlusion
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · intravenousAs given in this study (rats).
Source sentences
Summary
In safety and tolerability assessments, carnosine did not exhibit any evidence of adverse effects or toxicity.
1 context sentence(design, population, supporting numbers)
Summary · context
Efficacy and safety of carnosine treatment was evaluated in rat models of permanent or transient middle cerebral artery occlusion.
Report a problemFND-2325099406
07AnimalAnimal study (in vivo)Safety outcome
In rats receiving carnosine, organ histology showed no abnormalities.
In plain wordsIn rats receiving carnosine, organ tissue examinations found no abnormalities.
Peptide
L-carnosine
Outcome
No significant changeOrgan histology
Study
ratsn: not reported in source
permanent or transient middle cerebral artery occlusion
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · intravenousAs given in this study (rats).
Source sentences
Summary
Moreover, histological evaluation of organs, complete blood count, coagulation tests, and the serum chemistry did not reveal any abnormalities.
1 context sentence(design, population, supporting numbers)
Summary · context
Efficacy and safety of carnosine treatment was evaluated in rat models of permanent or transient middle cerebral artery occlusion.
Report a problemFND-2325099407
08AnimalAnimal study (in vivo)Safety outcome
In rats receiving carnosine, complete blood counts showed no abnormalities.
In plain wordsIn rats receiving carnosine, blood cell counts showed no abnormalities.
Peptide
L-carnosine
Outcome
No significant changeComplete blood count
Study
ratsn: not reported in source
permanent or transient middle cerebral artery occlusion
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · intravenousAs given in this study (rats).
Source sentences
Summary
Moreover, histological evaluation of organs, complete blood count, coagulation tests, and the serum chemistry did not reveal any abnormalities.
1 context sentence(design, population, supporting numbers)
Summary · context
Efficacy and safety of carnosine treatment was evaluated in rat models of permanent or transient middle cerebral artery occlusion.
Report a problemFND-2325099408
09AnimalAnimal study (in vivo)Safety outcome
In rats receiving carnosine, coagulation tests showed no abnormalities.
In plain wordsIn rats receiving carnosine, blood clotting tests showed no abnormalities.
Peptide
L-carnosine
Outcome
No significant changeCoagulation tests
Study
ratsn: not reported in source
permanent or transient middle cerebral artery occlusion
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · intravenousAs given in this study (rats).
Source sentences
Summary
Moreover, histological evaluation of organs, complete blood count, coagulation tests, and the serum chemistry did not reveal any abnormalities.
1 context sentence(design, population, supporting numbers)
Summary · context
Efficacy and safety of carnosine treatment was evaluated in rat models of permanent or transient middle cerebral artery occlusion.
Report a problemFND-2325099409
10AnimalAnimal study (in vivo)Safety outcome
In rats receiving carnosine, serum chemistry showed no abnormalities.
In plain wordsIn rats receiving carnosine, blood chemistry tests showed no abnormalities.
Peptide
L-carnosine
Outcome
No significant changeSerum chemistry
Study
ratsn: not reported in source
permanent or transient middle cerebral artery occlusion
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · intravenousAs given in this study (rats).
Source sentences
Summary
Moreover, histological evaluation of organs, complete blood count, coagulation tests, and the serum chemistry did not reveal any abnormalities.
1 context sentence(design, population, supporting numbers)
Summary · context
Efficacy and safety of carnosine treatment was evaluated in rat models of permanent or transient middle cerebral artery occlusion.
Report a problemFND-2325099410
11LabIn vitro (cells)Mechanism
In primary neuronal cultures and ex vivo brain homogenates, carnosine exhibited antiexcitotoxic activity.
In plain wordsIn lab tests using neuronal cultures and brain homogenates, carnosine showed activity against excitotoxicity.
Peptide
L-carnosine
Outcome
IncreaseAntiexcitotoxic activity
Study
n: not reported in source
primary neuronal cell cultures and ex vivo brain homogenates
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
In primary neuronal cell cultures and ex vivo brain homogenates, carnosine exhibited robust antiexcitotoxic, antioxidant, and mitochondria protecting activity.
Report a problemFND-2325099411
12LabIn vitro (cells)Mechanism
In primary neuronal cultures and ex vivo brain homogenates, carnosine exhibited antioxidant activity.
In plain wordsIn lab tests using neuronal cultures and brain homogenates, carnosine showed antioxidant activity.
Peptide
L-carnosine
Outcome
IncreaseAntioxidant activity
Study
n: not reported in source
primary neuronal cell cultures and ex vivo brain homogenates
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
In primary neuronal cell cultures and ex vivo brain homogenates, carnosine exhibited robust antiexcitotoxic, antioxidant, and mitochondria protecting activity.
Report a problemFND-2325099412
13LabIn vitro (cells)Mechanism
In primary neuronal cultures and ex vivo brain homogenates, carnosine exhibited mitochondria-protecting activity.
In plain wordsIn lab tests using neuronal cultures and brain homogenates, carnosine showed mitochondrial protection.
Peptide
L-carnosine
Outcome
IncreaseMitochondrial protection
Study
n: not reported in source
primary neuronal cell cultures and ex vivo brain homogenates
Outcome group
Mitochondrial function · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
In primary neuronal cell cultures and ex vivo brain homogenates, carnosine exhibited robust antiexcitotoxic, antioxidant, and mitochondria protecting activity.
Report a problemFND-2325099413

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.